Transmission blocking malaria vaccines
Transmission blocking malaria vaccines
复制标题
DOI：
10.1016/s0264-410x(00)00521-1
复制
发表时间：
2001-03-21
期刊：
影响因子：
5.5
通讯作者：
Carter, R
中科院分区：
文献类型：
--
作者：
Carter, R
针对疟疾的传播阻断疫苗（TBV）旨在诱导感染蚊子的寄生虫阶段的免疫力，以使TBV免疫的个体无法传播疟疾。由于疟疾感染主要是从感染性人类来源几百米内传播的，因此社区中使用的TBV将保护接种疫苗的人的直接社区。针对人类疟疾的两种主要物种，恶性疟原虫和Vivax的TBV。正在发展。两种疟原虫物种的候选TBV构建体已在动物系统中成功进行了测试，并且在人类的临床级材料中正在进行测试。 （c）2001 Elsevier Science Ltd.保留所有权利。
Transmission blocking vaccines (TBVs) against malaria are intended to induce immunity against the stages of the parasites which infect mosquitoes so that TBV-immunised individuals cannot transmit malaria. As malarial infections are transmitted mainly within a few hundreds of meters from an infectious human source, TBVs used within in a community would protect the immediate neighbourhood of the vaccinated individuals. TBVs against the two major species of human malaria, Plasmodium falciparum and P. vivax. are under development. Candidate TBV constructs for both Plasmodium species have been successfully tested in animal systems and testing is in progress with clinical grade material in humans. (C) 2001 Elsevier Science Ltd. All rights reserved.